More Indian drugs detained in EU as FTA talks progress ahead of Feb 10 summit
This article was originally published in Scrip
Even as the EU and India continue negotiations on a free trade agreement ahead of their next summit in February, another transiting consignment of Indian generics was seized in the EU late last year, much to the consternation of both the Indian industry and the Indian government. The seizure appears to have disrupted a long quiet period of sorts on the controversial issue of illegal detentions of transiting Indian consignments of generic medicines at EU ports over alleged violations of intellectual property rights.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.